Search

Background Non-small-cell lung cancer (NSCLC) is characterized by abnormalities of numerous signaling proteins that play pivotal roles in cancer development and progression. Many of these proteins have been reported to be correlated with clinical outcomes of NSCLC. However, none of them could provide adequate accuracy of prognosis prediction in clinical application. Methods A total of 384 resected NSCLC specimens from two hospitals in Beijing (BJ) and Chongqing (CQ) were collected. Using immunohistochemistry (IHC) staining on stored formalin-fixed paraffin-embedded (FFPE) surgical samples, we examined the expression levels of 75 critical proteins on BJ samples. Random forest algorithm (RFA) and support vector machines (SVM) computation were applied to identify protein signatures on 2/3 randomly assigned BJ samples. The identified signatures were tested on the remaining BJ samples, and were further validated with CQ independent cohort. Results A 6-protein signature for adenocarcinoma (ADC) and a 5-protein signature for squamous cell carcinoma (SCC) were identified from training sets and tested in testing sets. In independent validation with CQ cohort, patients can also be divided into high- and low-risk groups with significantly different median overall survivals by Kaplan-Meier analysis, both in ADC (31 months vs. 87 months, HR 2.81; P

Endocrine resistance is a major obstacle to hormonal therapy for breast cancers. Although reduced expression of estrogen receptor-α (ER-α) is a known contributing factor to endocrine resistance, the mechanism of ER-α downregulation in endocrine resistance is still not fully understood. Here we report that CUE domain-containing protein-2 (CUEDC2), a ubiquitin-binding motif-containing protein, is a key factor in endocrine resistance in breast cancer. We show that CUEDC2 modulates ER-α protein stability through the ubiquitin-proteasome pathway. Through the study of specimens from a large cohort of subjects with breast cancer, we found a strong inverse correlation between CUEDC2 and ER-α protein expression. Notably, subjects with tumors that highly expressed CUEDC2 had poor responsiveness to tamoxifen treatment and high potential for relapse. We further show that ectopic CUEDC2 expression impaired the responsiveness of breast cancer cells to tamoxifen. Therefore, our findings suggest that CUEDC2 is a crucial determinant of resistance to endocrine therapies in breast cancer.

Objective To explore the histological morphous,immunohistochemical and clinical features,differential diagnosis and prognosis of hepatic inflammatory angiomyolipoma(AML).Methods The clinical and pathological data of 5 patients with inflammatory hepatic AML were retrospectively analyzed followed by follow-up.The typical tissue was observed by immunohistochemical staining.Results Five patients(1 male and 4 females) aged from 21 to 48 years.Tumors were situated in left lobe of liver in 3 patients,and in right lobe in 2 patients.The tumors had a diameter of 5.5-10.0cm averaged 7.5cm.Generally,the tumors were grey-white on cut surface,without hemorrhage,necrosis and cystic degeneration.Microscopically,the tumors were consisted of spindle and epithelioid myocytes,irregular thick-walled blood vessels and adipose tissue in different proportion.A prominent infiltration of inflammatory cells,including lymphocytes,plasmocytes and histiocytes,in the background was noted in all cases.No obvious atypia and mitotic figure,and no hemorrhage,necrosis and cystic degeneration were noted in the tumor cells.It was immunohistochemically revealed that the tumor cells of all the 5 patients were positive in HMB-45,Melan-A,SMA and Vimentin,while negative in CD21,CD35,CK18,CK19,hepatocyte paraffin-1,AFP,EMA and CK.All the patients were undergone local hepatectomy without recurrence during a 3 to 9 years follow-up.Conclusion Inflammatory hepatic AML is one of the sub-types of AML,demonstrating a similar benign biologic behavior with classical AML.

Lipomatous hemangiopericytomas (LHPCs) are rare soft-tissue tumors that are histologically characterized by hemangiopericytomatous vasculature and the presence of mature adipocytes. We present the clinicopathological features of a case of gastric LHPC in a 56-year-old female, along with a literature review. Endoscopy and endoscopic ultrasound showed a submucosal tumor 0.8 cm across in the greatest dimension in the lesser curvature side of the gastric antrum. Grossly, the well-defined mass had a solid and tan-white cut surface admixed with myxoid regions and yellowish areas. Histological examination revealed a submucosal well-circumscribed lesion composed of cellular nodules with the classic appearance of an hemangiopericytoma admixed with clusters and lobules of mature adipocytes. The ill-defined tumor cells had weakly eosinophilic cytoplasm and contained spindled nuclei with occasional small nucleoli. Nuclei atypia and mitoses were absent, and no cellular atypia, necrosis or vascular invasion was observed. Immunohistochemistry showed that the tumor cells were diffusely positive for CD34, CD99, and vimentin and were focally reactive for bcl-2. This is the first known report of an LHPC in the stomach. The patient was followed for 12 mo without any evidence of metastasis or recurrence.